A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab (SDd) in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab (SDd) in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs